A series of 1,3-benzoxazole-4-carbonitriles was synthesized and evaluated for its antifungal activity, solubility, and metabolic stability. Among those compounds, 4-cyano-N,N,5-trimethyl-7-[(3S)-3-methyl-3-(methylamino)pyrrolidin-1-yl]-6-phenyl-1,3-benzoxazole-2-carboxamide (16b) exhibited potent in vitro activity against Candida species, higher water solubility, and improved metabolic stability compared to lead compound 1. Compound 16b showed potent in vivo efficacy against mice Candida infection models and good bioavailability in rats.
Increased incidence of invasive mycoses is often related to the growing use of broad-spectrum antibiotics, immunosuppressive agents, anti-cancer, and anti-AIDS drugs. [1] [2] [3] Although antifungal agents, such as polyenes, azoles, and candins, have shown potent efficacy against Candida species (spp.) in the treatment of systemic fungal infections, currently available drugs could not satisfy the increasing requirement for antifungal therapy in complex patient populations. This is because of the unfavorable properties, such as side effects, a narrow spectrum, and drug resistance. [4] [5] [6] [7] [8] [9] [10] These unresolved issues have caused a high rate of mortality and the spread of antifungal drug resistance. Therefore, new antifungal agents with a novel mode of action have been urgently required to open the possibility of a novel therapeutic approach.
We have reported the discovery of new antifungal agents possessing 1,3-benzoxazole-4-carbonitrile skeleton with a novel mode of action inhibiting the synthesis of b-1,6-glucan, which was known to play a key role in cellular growth and proliferation of Candida spp. 11) Among those 1,3-benzoxazole analogs, compound 1 showed potent antifungal activity against Candida spp. However, in vivo efficacy of 1 has not been observed in mice Candida albicans infection models. We considered the lack of in vivo efficacy of our compound was mainly due to its poor physicochemical properties such as high lipophilicity, low metabolic stability, and poor water solubility at pH 6.8 as shown in Fig. 1 . Therefore, we embarked on an exploration of the structure-activity relationships (SARs) of its peripheral analogs, as well as improvement of their physicochemical properties.
Initial SARs of this type of antifungal agent suggested that the cyano group at the 4-position and the methyl group at the 5-position are indispensable for potent antifungal activity. 11, 12) To develop SARs studies, we subdivided lead structure 1 into three sections: (A) phenyl ring, (B) aliphatic group, and (C) amino substituent. Each structural moiety was modified independently to clarify its function.
Herein, we would like to report the SARs and physicochemical properties of 1,3-benzoxazole analogs focusing on the relationship between physicochemical properties and in vivo activities in mice infection models.
Chemistry Various 1,3-benzoxazole-4-carbonitrile derivatives were synthesized from intermediates 4-7, which were prepared from useful hexa-substituted benzenes 2 and 3 as starting materials. 11) Compound 3 was converted to 1,3-benzoxazole intermediates 4 and 7 possessing ethoxycarbonyl or chloro group at the 2-position. 2-Cyclopropane derivative 5 was synthesized directly from 2, and then con- and Candida krusei ATCC 44507 (C. krusei). Minimum inhibitory concentration MIC-1 (the lowest drug concentration showing 80% growth inhibition compared to the control without drug) was determined for each compound by using the microdilution method previously described. 11) MIC-1s of the 6-substituted compounds 8a-o were summarized in Table 1 . Phenyl derivative 8a 11) showed high and broad activity against Candida spp. with MIC-1 ranging from 0.032 to 0.125 mg/ml, while the corresponding pyridin-2-yl 8b and pyridin-4-yl 8c demonstrated MIC-1 ranging from 1 to Ͼ4 mg/ml, respectively. Among the five-membered heteroaromatic derivatives, thienyl derivatives 8f and 8g showed a broad range of activity with MIC-1s ranging from 0.032 to 0.5 mg/ml. Vinyl derivative 8h was less active than 8a. These results indicate that the phenyl group is considered to be the best substituent at the 6-position showing potent antifungal activity. To investigate substituent effects on the phenyl group, we prepared various substituted phenyl derivatives 8i-o. Although 2-and 4-fluorophenyl derivatives 8i and 8k had only a moderate effect, corresponding 3-fluorophenyl analog 8j was found to be as potent as 8a. Replacing the 3-fluoro group with polar functionalities was not well tolerated, resulting in a two-to five-fold decrease in antifungal activities against C. albicans (derivatives 8l-o). These results indicated that substituents on the benzene ring at the 6-position had no profound effect on antifungal activity in comparison to the unsubstituted analog 8a.
Structure-Activity Relationships of 1,3-Benzoxazole-4-carbonitriles as Novel Antifungal Agents with Potent in Vivo Efficacy
Substituents at the 2-position influenced the antifungal activity as shown in Table 2 . Among the 2-carbonyl derivatives, dimethylcarbamoyl analog 11b demonstrated potent growth inhibition against Candida spp., which suggested that polar groups were tolerated for antifungal activity as well as aliphatic substituents such as tert-butyl and cyclopropyl group. On the other hand, when the cyclopropyl group in 8a was replaced by phenyl group, the inhibitory activity decreased significantly (12a). Interestingly, pyridin-2-yl analog 12b exhibited moderate inhibition against C. albicans (FLCZ-susceptible and -resistant) and C. glabrata (MIC-1ϭ0.25, 0.25, 0.032 mg/ml, respectively), while correspon- ding pyridin-3-yl and pyridin-4-yl derivatives 12c and 12d resulted in a loss of activity. Five-membered heteroaromatic analogs 12e and 12f showed activity similar to the pyridin-2-yl analog 12b. Alkylamino analogs 12g-i showed moderate activities, while pyrrolidin-1-yl 12j had only a small effect. Interestingly, 2-oxopyrrolidin-1-yl analog 14 exhibited enhanced activity, which indicates that the carbonyl group at this position has significant effect. These facts imply that the small aliphatic groups with carbon atoms up to four, such as tert-butyl and cyclopropyl, or polar functionalities with a particular combination of carbon, nitrogen, and oxygen atoms, such as alkylcarbamoyl, alkylamino, and 2-oxopyrrolidon-1-yl seem to be favorable. In the view of antifungal activities summarized in Tables 1  and 2 , we focused on the basic functionality at the 7-position for further optimization by means of 2-cyclopropyl and 2-CONMe 2 analogs 8a and 11b (Table 3) . Six-membered heterocycles and ethylenediamine structure at the 7-position resulted in diminished or complete loss of in vitro activity, whereas pyrrolidine groups showed high potency. Based on the hypothesis that the methyl group in the (dimethylamino)-pyrrolidinyl analog 8a was easily metabolized to a corresponding mono-methyl derivative, we prepared mono-methyl 15a. Unfortunately, replacement of NMe 2 into NHMe diminished antifungal activities. Similar results were obtained when 2-dimethylcarbamoyl 16a was evaluated. N-Demethylation of the terminal amine at the 7-positon resulted in a slight loss of in vitro potency, suggesting that the basic center such as NHMe and NH 2 was not appropriate for antifungal activity. We considered the loss of activity was caused by the existence of proton on the nitrogen atom, which might interfere with the binding of the amine center to the appropriate binding pocket or interaction with another binding site. However, we anticipated that the conversion of the NMe 2 group into the NHMe structure could improve aqueous solubility and metabolic stability. To make full use of the physicochemically profitable moiety, we decided to retain the NHMe and to seek other ways of enhancing in vitro activity. Therefore, we designed 3-methyl-3-(methylamino)pyrrolidin-1-yl to cover the unfavorable N-H moiety by the incorporation of 3-methyl group adjacent to the NHMe group. As a result, (3S)-3-methyl-3-(methylamino)pyrrolidin-1-yl analog 16b demonstrated potent activity against Candida spp. including C. krusei in spite of the existence of NHMe moiety on the pyrrolidine ring. These results suggest that a slight modification of 3-aminopyrrolidin-1-yl group at the 7-position influences in vitro activity including both the potency and the spectrum.
To investigate the relationship between the structure and physicochemical properties of the obtained compounds, we chose potent antifungal analogs 8j, 15a, 16a, and 16b. Their lipophilicity, water solubility, and metabolic stability were summarized in Table 4 . The initial focus of the optimization program was aimed at modifications of amine at the 7-position designed to increase the metabolic stability. Although antifungal activity was decreased, water solubility at pH 6.8 and metabolic stability were significantly improved by replacing (dimethylamino)pyrrolidin-1-yl with (methylamino)-pyrrolidin-1-yl at the 7-position. For example, water solubilities of 8j and 15a at pH 6.8 were 17 and 610 mg/ml, whereas metabolic stabilities of 8j and 15a for mouse microsomes were 4 and 70%, respectively. It is well known that dimethylamino structure NMe 2 is easily metabolized and that low lipophilicity could improve physicochemical property. Thus, 344 Vol. 59, No. 3 we considered the improvement of the physicochemical properties of our products was caused by the modification of the terminal alkylamino moiety at the 7-position and the consequent reduced lipophilicity. The second approach was the introduction of CONMe 2 at the 2-position as a low lipophilic moiety. Log D value was decreased by the introduction of the CONMe 2 group at the 2-position (Log Dϭ2.9 and 1.9 for 15a and 16a, respectively). Water solubility and metabolic stability of 16a were somewhat improved compared to the 2-cyclopropyl analog 15a. Surprisingly, compound 16b demonstrated the most potent antifungal activity and improved physicochemical properties. Although 16b possessed an additional methyl group on the pyrrolidin-1-yl at the 7-position, the Log D value was similar to that of demethyl analog 16a (Log Dϭ1.9 and 2 for 16a and 16b, respectively). Based on the results obtained above, the CONMe 2 group at the 2-position and the (3S)-3-methyl-3-(methylamino)pyrrolidin-1-yl group at the 7-position were regarded as effective in both physicochemical properties and antifungal activity.
The most potent antifungal agents 8j and 16b were selected as test compounds for acute systemic infection models in mice to evaluate the relationship between physicochemical properties and in vivo efficacy. Each compound was subcutaneously administrated at a dose of 20 and 40 mg/kg at 0 and 6 h after infection of C. albicans ATCC 90028. The in vivo efficacy was evaluated by survival rates 8 d after infection. As a result, no effect was observed for 8j at a dose of 20 mg/kg, whereas slightly prolonged survival days were observed at a dose of 40 mg/kg (Fig. 2) . On the other hand, 16b demonstrated apparently enhanced in vivo efficacy compared to 8j in a dose-dependent manner, indicated by a survival rate of 90% at the end of day eight (Fig. 3) . These results suggest that the in vivo efficacies of our compounds are strongly influenced by their physicochemical properties. Potent in vitro activities against C. grabrata and C. krusei were regarded as another attractive feature of our compounds, whereas reference compound FLCZ showed little potency against those Candida spp. In acute systemic infection models in mice infected with C. glabrata, 16b demonstrated excellent efficacy indicated by 100% survival at a dose of 3.3 mg/kg in eight days after infection (Fig. 4) .
Pharmacokinetic profiles of 16b were investigated for mice and rats as shown in Table 5 . It was noteworthy that a bioavailability of 16b in rats was evaluated as 68% suggesting the possibility of 16b as an orally and intravenously active agent. Thus, we anticipated that 16b could be administrated both intravenously and orally in clinical therapy.
Conclusion
In summary, we have discovered a series of 1,3-benzoxazole-4-carbonitrile derivatives with potent activity against Candida spp. Of these, 16b exhibited potent in vitro activity, water solubility, and improved metabolic stability as a potential preclinical candidate. Combination of antifungal activities and physicochemical properties was accomplished by introducing the hydrophilic CONMe 2 and the metabolically stable (3S)-3-methyl-3-(methylamino)pyrrolidin-1-yl groups at the 2-and 7-positions, respectively. Compound 16b demonstrated potent in vivo efficacy against mice Candida infection models and good bioavailability in rats.
Experimental
Chemistry Unless otherwise noted, materials were obtained from commercial suppliers and used without further purification. Melting points were taken on a Yanako MP-500D melting point apparatus and are uncorrected. Optical rotations were measured in a 0.5-dm cell at 25°C at 589 nm with a HORIBA SEPA-300 polarimeter. 1 H-NMR spectra were determined on a JEOL JNM-EX400 spectrometer. 13 C-NMR spectra were determined on a JEOL JNM-ECP500 spectrometer. Chemical shifts are reported in parts per million relative to tetramethylsilane as an internal standard. Significant 1 H-NMR data are tabulated in the following order: number of protons, multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad), and coupling constant(s) in hertz. Infrared (IR) spectra were obtained on a HORIBA FT-720 spectrometer or a JASCO FT/IR-6100 typeA. High-resolution mass spectra were obtained on a JEOL JMS-700 mass spectrometer under electron impact ionization conditions (EI), electron spray ionization conditions (ESI) or fast atom bombardment ionization conditions (FAB). Column chromatography refers to flash column chromatography conducted on Merck silica gel 60, 230-400 mesh ASTM. Thin-layer chromatography (TLC) was performed with Merck silica gel 60 F 254 TLC plates, and compound visualization was effected with a 5% solution of molybdophosphoric acid in ethanol, UV-lamp, iodine, or Wako Ninhydrin Spray. 11) (7.86 g, 32.1 mmol) and N,N-diisopropylethylamine (19.5 ml, 112 mmol) in AcOEt (300 ml) was added cyclopropanecarbonyl chloride (4.4 ml, 48.1 mmol) at 0°C and the mixture was stirred for 16 h at room temperature. AcOEt was added and the organic layer was washed with water and brine, dried over Na 2 SO 4 , filtered, and concentrated in vacuo. To a solution of the residue in toluene (80 ml) was added p-toluenesulfonic acid monohydrate (1.60 g), and the mixture was refluxed for 19 h. After cooling to room temperature, the mixture was diluted with AcOEt and filtrated. The precipitate was recrystallized from AcOEt to give the title compound 
68
a) AUC 0-24 h . b) AUC 0-6 h . c) Bioavailability calculated from the AUC ratio.
6.55.
2-Cyclopropyl-7-fluoro-5-methyl-6-phenyl-1,3-benzoxazole-4-carbonitrile (6)
A mixture of 5 (300 mg, 1.02 mmol), phenylboronic acid (256 mg, 2.03 mmol), potassium phosphate tribasic (432 mg, 2.03 mmol), and tetrakis(triphenylphosphine)palladium(0) (118 mg, 0.10 mmol) in 1,4-dioxane (6 ml) was stirred at 100°C for 17 h under nitrogen atmosphere. The mixture was cooled to room temperature. Satd NH 4 Cl aq. was added and the resultant mixture was extracted with AcOEt. The obtained organic layers were washed with brine, dried over Na 2 SO 4 , filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with n-hexane/AcOEtϭ8/1, v/v to afford the title compound (275 mg, 92%) as a white solid. MS (ESI) m/z: 293 (Mϩ1) 2-Chloro-7-fluoro-5-methyl-6-phenyl-1,3-benzoxazole-4-carbonitrile (7) A mixture of 3 (500 mg, 2.06 mmol) and ethylxantic acid potassium salt (1.00 g, 6.24 mmol) in pyridine (25 ml) was refluxed for 3 h. The reaction mixture was concentrated in vacuo and the residue was dissolved with AcOEt. The organic layer was washed with 1 M HCl aq., water, and brine, dried over Na 2 SO 4 , filtered, and concentrated in vacuo. A mixture of the residue and thionyl chloride (12 ml) was stirred for 1 h at 70°C. The reaction mixture was concentrated in vacuo and diluted with CH 2 Cl 2 . The organic layer was washed with 1 M NaOH aq., water, and brine, and then dried over Na 2 SO 4 
2-Cyclopropyl-7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-5-methyl-6-phenyl-1,3-benzoxazole-4-carbonitrile (8a)
To a solution of 6 (70 mg, 0.24 mmol) in dimethyl sulfoxide (DMSO) (2 ml) were added triethylamine (50 ml, 0.36 mmol) and (3S)-3-(dimethylamino)pyrrolidine (40 ml, 0.31 mmol), and then the mixture was stirred at 90°C for 14.5 h. AcOEt was added and the mixture was washed with brine, dried over Na 2 SO 4 , filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with CHCl 3 /MeOHϭ97/3, v/v to afford the title compound (64 mg, 69%) as a white solid. MS (ESI) m/z: 387 (Mϩ1) 
2-Cyclopropyl-7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-5-methyl-6-pyridin-2-yl-1,3-benzoxazole-4-carbonitrile (8b)
A mixture of 5 (200 mg, 0.68 mmol), 2-(tributylstannyl)pyridine (299 mg, 0.81 mmol), 2,6-ditert-butyl-4-methylphenol (2 mg), and bis(triphenylphosphine)palladium(II) dichloride (24 mg, 0.03 mmol) in toluene (4 ml) was refluxed for 17 h. The reaction mixture was filtered, and the filtrate was concentrated in vacuo. The residue was roughly purified by silica gel column chromatography eluting with n-hexane/AcOEtϭ3/1, v/v to afford 2-cyclopropyl-7-fluoro-5-methyl-6-pyridin-2-yl-1,3-benzoxazole-4-carbonitrile (184 mg) as a pale yellow oil. A mixture of the oil obtained above (184 mg), triethylamine (219 ml, 1.56 mmol), and (3S)-(dimethylamino)pyrrolidine (103 ml, 0.81 mmol) in DMSO (3.7 ml) was stirred at 90°C for 15 h. AcOEt was added, and the organic layer was washed with brine, dried over Na 2 SO 4 (1-methyl-1H-pyrrol-2-yl)-1,3-benzoxazole-4-carbonitrile (8d) Following the procedure as described for 8b, the title compound was prepared in 40% (2 steps -7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-5-methyl-6-vinyl-1,3- -7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-6-(2-fluorophenyl)-5-methyl-1,3-benzoxazole-4-carbonitrile (8i) Following the procedure as described for 6 and 8a, the title compound was prepared in 58% (2 steps 
2-Cyclopropyl

2-Cyclopropyl-7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-6-(3-fluorophenyl)-5-methyl-1,3-benzoxazole-4-carbonitrile (8j)
Following the procedure as described for 6 and 8a, the title compound was prepared in 58% (2 steps 
2-Cyclopropyl-7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-6-(4-fluorophenyl)-5-methyl-1,3-benzoxazole-4-carbonitrile (8k)
Following the procedure as described for 6 and 8a, the title compound was prepared in 71% ( 
6-(3-Aminophenyl)-2-cyclopropyl-7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-5-methyl-1,3-benzoxazole-4-carbonitrile (8l)
Following the procedure as described for 6 and 8a, the title compound was prepared in 94% (2 steps 
2-Cyclopropyl-7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-6-[3-(hydroxymethyl)phenyl]-5-methyl-1,3-benzoxazole-4-carbonitrile (8m)
Following the procedure as described for 6 and 8a, the title compound was prepared in 83% (2 steps) from 5 and 3-(hydroxymethyl)phenylboronic acid as a pale brown solid. MS (ESI) m/z: 417 (Mϩ1) 
2-Cyclopropyl-7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-6-(3-methoxyphenyl)-5-methyl-1,3-benzoxazole-4-carbonitrile (8n)
Following the procedure as described for 6 and 8a, the title compound was prepared in 47% (2 steps 
6-(3-Cyanophenyl)-2-cyclopropyl-7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-5-methyl-1,3-benzoxazole-4-carbonitrile (8o)
Following the procedure as described for 6 and 8a, the title compound was prepared in 23% (2 steps 
Ethyl 4-Cyano-7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-5-methyl-6-phenyl-1,3-benzoxazole-2-carboxylate (9)
To a solution of 4 (200 mg, 0.62 mmol) and triethylamine (112 ml, 0.62 mmol) in DMSO (12 ml) was added (3S)-3-(dimethylamino)pyrrolidine (94 ml, 0.74 mmol) in DMSO (2 ml) at 150°C, and then the mixture was stirred at 150°C for 1 h. The mixture was combined with AcOEt and water, extracted with AcOEt, and the organic layer was washed with brine, dried over Na 2 SO 4 
4-Cyano-7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-N,5-dimethyl-6-phenyl-1,3-benzoxazole-2-carboxamide (11a)
To a solution of methylamine hydrochloride (125 mg, 1.85 mmol) in CH 2 Cl 2 (2 ml) was added trimethylaluminum (1.03 M solution in n-hexane) (1.80 ml, 1.85 mmol), and the mixture was stirred for 40 min at room temperature. A solution of 4 (200 mg, 617 mmol) in CH 2 Cl 2 (2 ml) was added and the reaction mixture was stirred for 63 h at room temperature. The mixture was cooled in an ice bath and 1 M HCl was added. After stirring at room temperature, the mixture was extracted with CHCl 3 . The organic layer was washed with brine, dried over Na 2 SO 4 , filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with CH 2 Cl 2 /MeOHϭ100/1, v/v to afford 4-cyano-7-fluoro-N,5-dimethyl-6-phenyl-1,3-benzoxazole-2-carboxamide 10a (122 mg, 64%) as a yellow solid. Following the procedure as described for 9, the title compound was prepared in 12% from the solid obtained above as a yellow solid. 3-(dimethylamino)pyrrolidin-1-yl]-N,N,5-trimethyl-6-phenyl-1,3-benzoxazole-2-carboxamide (11b To a suspension of picolinic acid (271 mg, 2.2 mmol) in CH 2 Cl 2 (7 ml) were added oxalyl chloride (262 ml, 3 mmol) and catalytic N,N-dimethylformamide (DMF) at 0°C, and then the resulting mixture was stirred for 20 min at room temperature. N,Ndiisopropylethylamine (697 ml, 4 mmol) and 3 (485 mg, 2.0 mmol) were added and the mixture was stirred for 2 h. The reaction mixture was diluted with CHCl 3 , washed with brine, dried over Na 2 SO 4 , filtered, and concentrated in vacuo. To a solution of the residue in xylene (20 ml) was added catalytic p-toluenesulfonic acid monohydrate, and then the mixture was refluxed for 12 h. The mixture was diluted with CHCl 3 , washed with brine, dried over Na 2 SO 4 , filtered, and concentrated in vacuo. The residue was roughly purified by silica gel column chromatography eluting with CHCl 3 /MeOHϭ98/2, v/v to afford 7-fluoro-5-methyl-6-phenyl-2-pyridin-2-yl-1,3-benzoxazole-4-carbonitrile.
4-Cyano-7-[(3S)-
A mixture of the carbonitrile, (3S)-3-(dimethylamino)pyrrolidine (129 ml, 1.02 mmol), and triethylamine (150 ml) in DMSO (8 ml) was stirred at 100°C for 3 h. The reaction mixture was concentrated in vacuo, diluted with CHCl 3 , washed with brine, dried over Na 2 SO 4 , filtered, and concentrated in vacuo. 06 (1H, m), 2.16 (6H, s), 2.23 (3H, s), 2.50-2.60 (1H, m) , 3 .02 (1H, t, Jϭ9.2 Hz), 3.37-3.56 (3H, m), 7.13-7.17 (1H, m) pyridin-4-yl-1,3-benzoxazole-4-carbonitrile (12d) Following the procedure as described for 12b, the title compound was prepared in 21% (3 steps (1H, m), 1.98-2.06 (1H, m), 2.16 (6H, s), 2.24 (3H, s), 2.50-2.61 (1H,  m), 3.04 (1H, t, Jϭ9.2 Hz), 3.36-3.48 (2H, m), 3.49-3.56 (1H, m), 7.13-7.16 (1H, m), 7.26-7.29 (1H, m), 7.35-7.46 (3H, m) pyrrol-2-yl)-6-phenyl-1,3-benzoxazole-4-carbonitrile (12e) A mixture of 7 (200 mg, 0.70 mmol), 1-methyl-2-(tributylstannyl)pyrrole (389 mg, 1.05 mmol), 2,6-di-tert-butyl-4-methylphenol (2 mg), and bis(triphenylphosphine)palladium(II) dichloride (49 mg, 0.07 mmol) in toluene (20 ml) was refluxed for 3 h. The reaction mixture was filtered and the filtrate was concentrated in vacuo. The residue was roughly purified by silica gel column chromatography eluting with n-hexane/AcOEtϭ5/1, v/v to afford 7-fluoro-5-methyl-2-(1-methyl-1H-pyrrol-2-yl)-6-phenyl-1,3-benzoxazole-4-carbonitrile (50 mg) as a pale yellow oil. A mixture of the carbonitrile, triethylamine (100 ml), and (3S)-(dimethylamino)pyrrolidine (53 ml, 0.42 mmol) in DMSO (2 ml) was stirred at 110°C for 3.5 h. The reaction mixture was concentrated in vacuo, diluted with CHCl 3 , washed with brine, dried over Na 2 SO 4 , filtered, and concentrated in vacuo. 35 (2H, m), 7.12 (1H, d, Jϭ7.3 Hz), 7.20-7.25 (1H, m) 7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-5-methyl-6-phenyl-1,3-benzoxazole-4-carbonitrile (12i) Following the procedure as described for 12g, the title compound was prepared in 53% (2 steps 
7-[(3S)-3-(Dimethylamino)pyrrolidin-1-yl]-5-methyl-6-phenyl-2-
7-[(3S)-3-(Dimethylamino)pyrrolidin-1-yl]-5-methyl-2-(1-methyl-1H-
Ethyl 4-({4-Cyano-7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-5-methyl-6-phenyl-1,3-benzoxazol-2-yl}amino)butanoate (13)
To a solution of 7 (213 mg, 0.743 mmol) in CH 2 Cl 2 (7 ml) were added ethyl 4-aminobutyrate hydrochloride (149 mg, 0.892 mmol) and N,N-diisopropylamine (303 ml, 1.78 mmol) at 0°C, and then the mixture was stirred at room temperature for 15 h. The mixture was concentrated in vacuo and diluted with AcOEt. The mixture was washed with brine, dried over Na 2 SO 4 , filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with n-hexane/AcOEtϭ1/1, v/v to afford ethyl 4-({4-cyano-7-fluoro-5-methyl-6-phenyl-1,3-benzoxazol-2-yl}amino)butanoate (279 mg, 99%) as a white solid. Following the procedure as described for 12g, the title compound was prepared in 49% from the solid obtained above as a brown oil. To a solution of the foam (90.0 mg, 0.201 mmol) in CH 2 Cl 2 (2 ml) was added thionyl chloride (43.5 ml, 0.603 mmol) and the mixture was stirred at room temperature for 1 h. The reaction mixture was concentrated in vacuo and the residue was dissolved with pyridine (2 ml). After stirred at 70°C for 1 h, the mixture was concentrated in vacuo, diluted with CHCl 3 , and washed with brine. The organic layer was dried over Na 2 SO 4 2821, 2773, 2210, 1743, 1593, 1552, 1468, 1441, 1408, 1389, 1363 5-methyl-7-(4-methylpiperazin-1-yl)-6-phenyl-1,3- Cyano-N,N,5-trimethyl-7-[(3S)-3-methyl-3-(methylamino)pyrrolidin-1-yl]-6-phenyl-1,3-benzoxazole-2-carboxamide (16b) To a solution of 10b (400 mg, 1.24 mmol) in DMSO (6 ml) were added 23 (318 mg, 1.48 mmol) and triethylamine (241 ml, 1.73 mmol) in DMSO (1 ml) at 150°C, and then the mixture was stirred at 150°C for 30 min. The mixture was concentrated in vacuo, diluted with AcOEt. The mixture was washed with brine, dried over Na 2 SO 4 , filtered, and concentrated in vacuo. The residue was roughly purified by silica gel column chromatography eluting with n-hexane/AcOEtϭ1/2, v/v to afford the crude Boc-16b as a yellow foam. To a solution of the crude foam in CH 2 Cl 2 (3 ml) was added trifluoracetic acid (6 ml) at 0°C and the mixture was stirred at room temperature for 5 h. The mixture was concentrated in vacuo and neutralized with satd NaHCO 3 aq. The mixture was extracted with CHCl 3 and the organic layer was concentrated in vacuo. 11) Test organisms were purchased from the American Type Culture Collection (Rockville, MD, U.S.A.), the Institute for Fermentation Osaka (Osaka, Japan), or Teikyo Institute of Medical Micology (Tokyo, Japan). Initial cell densities (1ϫ10 3 -1ϫ10 4 cells/ml) and incubation times (18-72 h) were decided for each strain in consideration of their growth speed. The fungi were incubated at 37°C. Follwing incubation, OD 600 was measured with a Wallac 1420 ARVOsx multi-label counter (Wallac, Tokyo, Japan) and MIC-1s were calculated. Compounds were tested at different concentrations ranging from 0.016 to 128 mg/ml.
4-
Distribution Coefficient (Log D) The distribution coefficients (Log D) were determined by the shake-flask method. Four hundred micromolar of compound solution of each compound in a 2 ml n-octanol-2 ml PBS solution was placed on a shaker for 30 min at pH 7.4. After centrifuging each solution separately at 3000 rpm for 10 min, an LC/MS method was used to assay each layer. The LC/MS system consisted of an 1100 Series LC/MSD (Agilent) and an X Terra ® MSC18 column (30ϫ3.0 mm, 3.5 mm) (Waters). The mobile phase was a 10 mM ammonium acetate buffer (pH 4.5)/0.05% (v/v) acetic acid mixture in acetonitrile with a gradient condition (95/5-
